Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group

被引：28

作者：

Schnell, Oliver ^{[1
]}

Standl, Eberhard ^{[1
]}

Catrinoiu, Doina ^{[2
]}

Genovese, Stefano ^{[3
]}

Lalic, Nebojsa ^{[4
]}

Skra, Jan ^{[5
]}

Valensi, Paul ^{[6
]}

Ceriello, Antonio ^{[7
]}

机构：

[1] Helmholtz Ctr Munich, Forschergrp Diabet eV, Ingolstaedter Landstr 1, D-85764 Munich, Germany

[2] Clin Cty Emergency Hosp Constanta, Internal Med Dept, Tomis Blvd 145, Constanta 900591, Romania

[3] IRCCS MultiMed, Diabet & Metab Dis Unit, Via Milanese 300, I-20099 Sesto San Giovanni, MI, Italy

[4] Univ Belgrade, Clin Endocrinol Diabet & Metab Dis, Clin Ctr Serbia, Fac Med, Belgrade 11000, Serbia

[5] Charles Univ Prague, Dept Internal Med 3, Fac Med 1, U Nemocnice 1, Prague 12808 2, Czech Republic

[6] Univ Paris 13, Dept Endocrinol Diabetol Nutr, Hop Jean VERDIER, CINFO,CRNH IdF, Ave 14 Juillet, F-93140 Bondy, France

[7] Inst Invest Biomed August Pi & Sunyer IDIBAPS, Mallorca 183, Barcelona 08036, Spain

来源：

CARDIOVASCULAR DIABETOLOGY | 2016年 / 15卷

关键词：

Metformin; Acarbose; Insulin Glargine; Insulin Degludec; European Medicine Agency Guideline;

D O I：

10.1186/s12933-016-0357-x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group was held during the annual meeting on 30 October 2015 in Munich. This summit was organized in light of recently published and numerous ongoing CVOTs on diabetes, which have emerged in response to the FDA and the EMA Guidelines. The CVOT Summit stands as a novel conference setup, with the aim of serving as a reference meeting for all topics related to CVOTs in diabetes. Members of the steering committee of the D&CVD EASD Study Group constitute the backbone of the summit. It included presentations of key results on DPP-4 inhibitors, GLP-1-Analogues, SGLT-2 inhibitors, acarbose and insulins. Diabetologists' and cardiologists' perspective on the potential need of new study designs were also highlighted. Furthermore, panel discussions on the design of CVOTs on diabetes were included in the program. The D&CVD EASD Study Group will continue its activity. In-depth discussions and presentations of new CVOTs like LEADER, will be resumed at the 2nd CVOT on diabetes of the D&CVD EASD Study Group, which will be held from 20-22 October 2016 in Munich (http://www.dcvd.org).

引用

页数：3

共 2 条

[1]

[Anonymous], 2008, GUID IND DIAB MELL E

[2]

[Anonymous], Guideline on Clinical Investigation of Medicinal Products for the Treatment of Sepsis.

← 1 →